Jobs
View more job listings or post a job
Revolution Medicines Senior Scientist, DMPK and Clinical Pharmacology
Quintara Discovery Research Scientist (Bioanalysis)
Quintara Discovery Research Scientist (Bioanalysis)
Chinook Therapeutics, Inc Sr. Scientist, In Vivo Pharmacology (Team Lead)
AbVision Senior/Principle Scientist (Immunology/Cell Biology)
Genentech, Inc. Associate Scientist, Biomarker Mass Spectrometry Laboratory  
Genentech, Inc. Senior Scientific Researcher for Biomarker Mass Spectrometry Laboratory
Genentech Inc. Contractor Scientist–Drug Metabolism
Genentech, Inc. Associate Scientist / Scientist, Biotransformation and ADME of New Modality  
Genentech, Inc. Scientist / Sr. Scientist, Drug Metabolism and Pharmacokinetics  
Post a job

Symposium

[Postponed due to COVID-19] No More Undruggables: Unconventional Approaches for Drug Discovery and Design - prodrugs, PROTACS, fragment-based design, directed evolution and beyond


Speakers: Carolyn Bertozzi (Stanford), Michelle Arkin (UCSF), Adrian Gill (Revolution Medicines), Michael Keiser (UCSF), Mark Smith (Stanford), Maureen Hillenmeyer (Hexagon Bio), Ian Seiple (UCSF), Daniel Erlanson (Frontier Medicines), Chaitan Khosla (Stanford)
Organizers: Toni Kline, PhD
Date: 2020-05-22
Time: 8:30-17:00 Pacific Time
Registration fee: (USD): Regular: $195; Academic: $125; Students & Unemployed: $35
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date: (2)Applied StemCell; WuXi Apptec
Registration: http://www.PBSS.org
Registration deadline:2020-05-20  (it will close sooner if the seating cap is reached)

About the Topic

Proteins function in a physiological environment of access barriers, regulators, facilitators, and partners. In many therapeutic ecologies, single drug-single target does not apply. To target these dynamics new modalities of both drug and drug discovery are being explored. This Symposium will highlight some emerging ones.  

Part A. Beyond Target Binding

Classic drug-target interactions are typically viewed as a non-covalent association of the small molecule drug with a single protein receptor, active, or allosteric site; this binding blocks protein reaction with the native agonist or substrate, and the offending signal is quenched.  The limitations of this vision become clear when in vitro results do not translate into in vivo efficacy.

Engineering the small molecule to accommodate and exploit the complexities of ADME-- and systems biology-- is now being accomplished in a number of creative ways: Much as we once naively talked about “junk DNA” and “undruggable” targets, we now have the insight and tools to understand the therapeutic potential embedded in complex biological systems.

Part B. Towards the rest of that chemical space.

Library (high-throughput or more modest) screening, and modifications of known drugs have been engines of the discovery process for a century. Along with combinatorial chemistry and computer assisted drug discovery (CADD), these methods have brought thousands of molecules to the clinic. But a certain ”drug-like” sameness often appears across therapeutic groups.  Perhaps for good reason (ADME, PK properties are optimized according to established conventions), but this sameness is at the expense of exploring truly novel chemical space. Happily, the discovery process is not static, and technologies are emerging to identify less obvious and less familiar-looking molecules.  In the oncology and antibiotic spaces, drugs arising from these methods might encounter less resistance.

 

Topics & Speakers:

  • LYTACs/PROTACsCarolyn Bertozzi, PhD, Professor of Chemical & Systems Biology and Radiology, Stanford University
  • Protein-protein interactionsMichelle Arkin, PhD, Co-director, Small Molecule Discovery Center (SMDC), Professor, Pharmaceutical Chemistry, UCSF    
  • Allosteric inhibitorsAdrian Gill, PhD, VP Medicinal Chemistry and CMC, REVOLUTION Medicines
  • Systems pharmacology and forward polypharmacologyMichael Keiser, PhD, Professor, Institute for Neurodegenerative Diseases, UCSF
  • Discovery at the academia/biotech borderline: Mark Smith, PhD, Head, ChEM-H Medicinal Chemistry Knowledge Center, Stanford University
  • AI meets fermentation: Maureen Hillenmeyer, PhD, CEO, Hexagon Bio      
  • Access to complex natural products: Ian Seiple, PhD, Professor in Residence, Cardiovascular Research Institute, UCSF
  • Fragment based drug discoveryDaniel Erlanson, PhD, VP of Chemistry, Frontier Medicines
  • Directed evolution: Chaitan Khosla, PhD, Professor of Chemical Engineering and Chemistry, Stanford University


2020-09-17, Regulated Large Molecule Bioanalysis: Fundamentals, the New FDA Guidance and Beyond
2020-10-19, [New Date] Preclinical and Clinical Development of Cell-based Immunotherapies: Translational PKPD, Safety, Biomarker, CMC, Clinical Pharmacology & Clinical Trials
2021-07-29, Development of Inhalation Therapeutics (a joint symposium by AAPS-BADGE / PBSS / Genentech)
┬ęPharmaceutical & BioScience Society, International; Last Modified: 7/5/2020; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Hypha Discovery Ltd. Experts in scalable synthesis & purification of drug metabolites, including CYP, AOX, FMO metabolites as well as O-, N-, acyl glucuronides & sulfates.
Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad